S
Salomon M. Stemmer
Researcher at Rabin Medical Center
Publications - 215
Citations - 12740
Salomon M. Stemmer is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 43, co-authored 189 publications receiving 9651 citations. Previous affiliations of Salomon M. Stemmer include University of New South Wales & Tel Aviv University.
Papers
More filters
Journal ArticleDOI
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
István Láng,Moshe Inbar,Zsuzsanna Kahán,Richard Greil,Semir Beslija,Salomon M. Stemmer,Bella Kaufman,Z. Zvirbule,Günther G. Steger,Diethelm Messinger,Thomas Brodowicz,Christoph C. Zielinski +11 more
TL;DR: Safety data from a randomised, phase III study evaluating first-line bevacizumab plus paclitaxel or capecitabine for locally recurrent or metastatic breast cancer is in-line with safety data reported in previous phase III trials.
Journal ArticleDOI
The cost and value of cancer drugs – are new innovations outpacing our ability to pay?
TL;DR: This commentary discusses the current problems and anticipate the future challenges of cancer care, and analyzes how it is playing out in an Israeli health plan with over two million members by analyzing how the cost-effectiveness and budget impact of individual drugs are changing.
Journal ArticleDOI
Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Christoph C. Zielinski,István Láng,Semir Beslija,Zsuzsanna Kahán,Moshe Inbar,Salomon M. Stemmer,Rodica Anghel,Damir Vrbanec,Diethelm Messinger,Thomas Brodowicz +9 more
TL;DR: This exploratory analysis indicates that HFS occurrence is a strong predictor of prolonged PFS and OS in patients receiving BEV–CAP for LR/mBC.
Journal ArticleDOI
Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
Noa Eliakim-Raz,Amos Stemmer,N. Ghantous,Asaf Ness,Muhammad Awwad,Yaara Leibovici-Weisman,Salomon M. Stemmer +6 more
TL;DR: This cohort study evaluates the response to a third and fourth SARS-CoV-2 BNT162b2 vaccine dose among individuals aged 60 years or older by evaluating antispike immunoglobulin G antibody titers before and after each dose.
Journal ArticleDOI
First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.
Gabriel N. Hortobagyi,Shani Paluch-Shimon,Katarína Petráková,Cristian Villanueva,Arlene Chan,Arnd Nusch,Yoon Sim Yap,Lowell L. Hart,Anne Favret,Norbert Marschner,Gabe S. Sonke,Hege O. Ohnstad,Carlos L. Arteaga,Fei Su,Wei He,M. Miller,Salomon M. Stemmer +16 more
TL;DR: First-line RIB + LET improved investigator-assessed progression-free survival (PFS) vs placebo (PBO) + LET in postmenopausal pts with HR+, HER2– AB, in MONALEESA-2.